Onco Actu du 17 novembre 2017

	1. Biologie
Growing tiny tumours in the lab could help treat cancer [The Economist] The “tumouroids” mimic real cancers much more closely than traditional cell cultures.
	2. Etiologie
Johnson & Johnson wins California lawsuit claiming asbestos in talc caused cancer [Reuters] The Los Angeles Superior Court jury’s verdict came in the first trial centering on claims that J&J’s talc products contained asbestos. J&J is separately battling thousands of cases claiming those products can also cause ovarian cancer.
	3.3 Prévention - Vaccins
Media coverage of HPV vaccine increased reports of adverse events – Expert Reaction [Science Media Centre] Some of the adverse events reported after the rollout of the HPV vaccine in New Zealand are likely to have been related to news coverage rather than the vaccine itself, according to a new Australian study.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA clears next-gen tumor sequencing test from Memorial Sloan Kettering [EndPoints] In conjunction with the announcement, FDA also laid out a new framework for clearing NGS-based tumor profiling tests based on recommendations from accredited third-party reviewers, the first of which is NYSDOH.
	5.10 Traitements - Essais
ASCO Expands TAPUR Study Enrollment After Promising Initial Treatment Outcomes Seen [ASCO] Four Cohorts to Enroll Additional Patients; Total Enrollment Exceeds 500 as Immunotherapy Combo is Added.
	5.12.2 Immunothérapies - CAR-T
At Seattle Children’s, Another Piece of Ambitious CAR-T Plan in Place [Xconomy] As part of their plan to prevent relapses, Seattle Children’s researchers want to find out if a different tumor target, CD22, can be an Achilles’ heel of tumors that bounce back after a CD19-directed attack. In about a quarter of all patients treated with CD19-directed T cells, the cancer mutates and comes back without CD19, leaving them invisible to the T cells.
Celgene Corporation and bluebird bio Announce bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma [Celgene] Designations based on preliminary clinical data from ongoing phase I study of bb2121 in heavily pre-treated multiple myeloma.
FDA, EMA put a star CAR-T from bluebird and Celgene on the VIP list [EndPoints] During the last ASCO bluebird bio and its partners at Celgene angled into center stage with an update on their BCMA-targeting CAR-T drug bb2121 for multiple myeloma that wowed the cancer crowd.
Cancer immunotherapy company tries to explain deaths in recent trial [Science] Sadly, fatalities are always a risk when developing therapies for advanced cancers, Gottschalk says. “This expectation that you can develop therapies for life-threatening diseases [without deaths] is rather naïve,” he says.
Message from the President [EBMT] EBMT is committed to allow access of all patients to CAR-T cell therapy. However, the announced price tags for such products appear to be quite prohibitive.
	5.12.8 Immunothérapies - Economie
How can new launches mimic Keytruda, Harvoni, and Opdivo? A new report has some ideas [FiercePharma] The report is designed to help biopharma companies prioritize their R&D projects and recoup expenses.
	5.3.4 Traitements - AMM (FDA, EMA)
Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma [Pfizer] “This adjuvant therapy is the first-of-its-kind and a remarkable clinical development for these patients who before today, have been restricted to a wait and see approach.”
Roche nabs blockbuster FDA approval for Hemlibra, big label expansion for Gazyva [FiercePharma] The FDA came through with another important decision for Gazyva. The drug won a first-line follicular lymphoma nod that Jefferies analysts expect will bring an estimated $3.5 billion at peak. Again, they acknowledged they're significantly above consensus of $1.2 billion by 2021.
FDA approves Roche’s Gazyva for previously untreated advanced follicular lymphoma [Roche] The first treatment option to demonstrate superior progression-free survival over standard-of-care Rituxan-based therapy.
FDA expands approval of Sutent to reduce the risk of kidney cancer returning [FDA] The approval of Sutent for the adjuvant treatment of renal cell carcinoma was based on a randomized trial of 615 patients with high risk of recurrent renal cell carcinoma following nephrectomy.
FDA backs Roche's Gazyva in first-line follicular lymphoma [Reuters] Gazyva is a follow-on drug to Rituxan, which at more than $7 billion in annual sales is Roche’s top seller but which has lost patent protection in Europe, exposing it to cheaper copies.
FDA expands approval for Pfizer cancer drug Sutent [Reuters] A clinical trial showed that after five years, 59.3 percent of patients treated with Sutent had not had a recurrence of cancer or death compared with 51.3 percent of patients taking a placebo.
	5.4 Traitements - Economie
Two breast cancer drugs get NHS approval [Cancer Research UK] Cancer Research UK – who funded the Nobel Prize-winning researchers whose work underpinned the drugs’ development – welcomed the announcement.
	5.8.2 ASH - Pharma
Let the jousting begin: Which top biopharma companies are looking to make a splash at ASH? [EndPoints] Anyone who follows oncology knows the field has attracted so much attention and research money that it sparks a continual eruption of biopharma news as companies joust over blockbuster markets. That’s kept me busy this year with a string of global confabs — as ASCO becomes just one big event in a frenzied competition. So now I’ll be attending ASH in Atlanta in early December for the first time.
	6. Lutte contre les cancers
National organizations support outreach efforts for NIH’s All of Us Research Program [NIH] This inaugural group of organizations will receive a combined $1 million to help educate their communities about the benefits of participation in this landmark project to accelerate breakthroughs in precision medicine.
	6.11 Patients
This Is What Sex After Gynecological Cancer Is Really Like [Self] "Sex felt like someone taking a hammer to my vagina."
	6.4 Médico-éco
High-value oncology practices include “support for the patient journey” [Stanford Medicine] “Our findings suggest that many of the places that provide high-value care are also particularly good at providing these often unreimbursed, non-medical services,” Blayney said.
	6.6 Publications
The original preprint system was scientists sharing photocopies. Then journal publishers screamed [STAT] The preprint system has worked so well in basic biomedical research that bioRxiv plans to launch a preprint site for clinical trials and epidemiology, Sever said. It will be a partership between Cold Spring Harbor Lab and Yale University, he said, and should go live in 2018.
Why we should care that many editors of top medical journals get healthcare industry payments [HealthNewsReview] About half the editors at the most prestigious medical journals in the U.S. receive payments from the pharmaceutical or medical device industries. But only 30 percent of these journals make it clear to readers what their policies are regarding such conflicts of interest.
	6.7.1 Bioinformatique
AI Can Be Made Legally Accountable for Its Decisions [MIT Technology Review] Computer scientists, cognitive scientists, and legal scholars say AI systems should be able to explain their decisions without revealing all their secrets.